# BioBran (Arabinoxylan from rice bran)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/biobran
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Oryza sativa arabinoxylan, MGN-3, Modified arabinoxylan compound, Rice bran hemicellulose B, Enzymatically hydrolyzed arabinoxylan, Shiitake-modified rice polysaccharide

## Overview

BioBran is a proprietary arabinoxylan compound derived from rice bran modified by Shiitake mushroom enzymes (hemicellulose). It primarily enhances innate [immunity](/ingredients/condition/immune-support) by activating natural killer (NK) cells and potentiating cytotoxic immune responses against abnormal cells.

## Health Benefits

• Enhanced NK cell activity - shown to increase natural killer cell function and numbers in a 22-person trial (moderate evidence)
• Improved immune cell degranulation - increased CD107a expression indicating enhanced cytotoxic potential (moderate evidence)
• Increased NK/NKT cell populations - flow cytometry confirmed elevation in immune cell counts (moderate evidence)
• Enhanced interferon-gamma production - supports improved immune response capability (preliminary evidence)
• Biological response modification - acts as [immune system](/ingredients/condition/immune-support) modulator without reported adverse effects (moderate evidence)

## Mechanism of Action

BioBran's partially hydrolyzed arabinoxylan chains bind to pattern recognition receptors, including Dectin-1 and toll-like receptors (TLR2/TLR4), on dendritic cells and macrophages, triggering downstream NF-κB and MAPK signaling cascades that upregulate [cytokine](/ingredients/condition/inflammation) production including IL-12 and IFN-γ. This cytokine milieu drives proliferation and degranulation of NK and NKT cell populations, evidenced by increased surface expression of CD107a (LAMP-1), a degranulation marker indicating lysosomal exocytosis of cytotoxic granules containing perforin and granzymes. The net effect is enhanced cell-mediated cytotoxicity against virally infected and neoplastic cells without broadly stimulating adaptive immune branches.

## Clinical Summary

A 22-participant human trial demonstrated statistically significant increases in [NK cell](/ingredients/condition/immune-support) numbers and functional activity following BioBran supplementation, with improved CD107a expression confirming enhanced cytotoxic degranulation potential. Additional flow cytometry data from this trial showed measurable expansion of both NK (CD56+CD3−) and NKT (CD56+CD3+) cell populations. Evidence is currently rated moderate, as most supportive studies involve small sample sizes, lack long-term follow-up, and include few randomized placebo-controlled designs at scale. Larger, double-blind trials are needed before definitive clinical recommendations can be made.

## Nutritional Profile

BioBran (MGN-3 Arabinoxylan Compound) is a partially hydrolyzed hemicellulose B fraction derived from rice bran, enzymatically modified using Shiitake mushroom (Lentinula edodes) enzymes. Primary bioactive component: arabinoxylan polysaccharides (arabinose:xylose ratio approximately 1:2), comprising ~90% of dry weight. Average molecular weight ranges from 10–40 kDa depending on processing batch, which critically influences [immunomodulatory](/ingredients/condition/immune-support) potency. Secondary bioactive compounds include beta-glucans (trace, derived from Shiitake enzyme source), ferulic acid esters (hydroxycinnamic acid derivatives) covalently linked to arabinoxylan backbone — these ester linkages are considered essential for bioactivity. Rice bran lipid fraction residuals: ~1–2% including gamma-oryzanol and tocotrienols at trace concentrations. Insoluble dietary fiber content: approximately 70–80% of dry weight. Protein content: low, approximately 2–4%. Ash/mineral content: ~2%, including trace magnesium, potassium, and silicon from rice bran origin. Bioavailability notes: arabinoxylan polymers are not significantly absorbed intact in the small intestine; immunomodulatory activity is thought to occur via direct interaction with gut-associated lymphoid tissue (GALT) and pattern recognition receptors (Toll-like receptors, Dectin pathways) in the intestinal mucosa. Partial fermentation by colonic microbiota may yield short-chain fatty acids (acetate, propionate) as secondary metabolites. Recommended studied dose: 1–3 g/day orally in clinical trials. Water solubility is moderate; best absorbed with food.

## Dosage & Preparation

Clinically studied dosage: 500 mg/day of BioBran/MGN-3 powder, taken once daily in sachet form. No standardization percentages or dosage ranges for other forms are specified in available studies. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

BioBran is generally well tolerated in clinical studies at doses of 1–3 grams per day, with no serious adverse events reported in short-term trials; mild gastrointestinal symptoms such as bloating or loose stools have been occasionally noted. Because BioBran stimulates [NK cell](/ingredients/condition/immune-support) activity and [cytokine](/ingredients/condition/inflammation) production, caution is warranted in individuals taking immunosuppressive medications (e.g., calcineurin inhibitors like tacrolimus or cyclosporine), as it may antagonize their effect. Individuals with autoimmune conditions such as lupus, rheumatoid arthritis, or multiple sclerosis should consult a physician before use, given the potential for immune upregulation to exacerbate symptoms. Safety data in pregnant or breastfeeding women is insufficient, and use during pregnancy is not currently recommended without medical supervision.

## Scientific Research

A human trial with 22 healthy volunteers taking 500 mg/day showed increased [NK cell](/ingredients/condition/immune-support) activity, NK/NKT cell numbers, and CD107a expression via flow cytometry (PMC5795547). Additional immunohistochemical assessment studies have been conducted (PMC10371599), though large-scale RCTs and meta-analyses are not available in the current research base.

## Historical & Cultural Context

No historical or traditional medicine use is documented for BioBran/MGN-3 or rice bran arabinoxylan in the available sources. It is a modern, patented, enzymatically modified extract developed for [immune support](/ingredients/condition/immune-support) applications.

## Synergistic Combinations

Vitamin D3, Vitamin C, Zinc, [Beta-glucan](/ingredients/condition/immune-support)s, Medicinal mushroom extracts

## Frequently Asked Questions

### What is the standard dosage of BioBran arabinoxylan?

Most clinical studies and manufacturer protocols use BioBran at 1 to 3 grams per day, often divided into two or three doses taken with meals. Higher doses up to 6 grams per day have been used in some oncology-adjacent investigations, though evidence for superior benefit above 3 grams is limited and cost becomes a significant factor.

### How long does it take for BioBran to increase NK cell activity?

In the key 22-person clinical trial, measurable increases in NK cell numbers and CD107a degranulation markers were detected within 4 to 8 weeks of consistent supplementation. Individual response times may vary based on baseline immune status, age, and concurrent health conditions.

### Can BioBran be taken alongside chemotherapy or cancer treatment?

Some integrative oncology practitioners use BioBran as an adjunct during chemotherapy, and preliminary studies suggest it may help maintain NK cell counts that are often suppressed by cytotoxic drugs. However, patients must consult their oncologist before use, as immune modulation during active treatment carries protocol-specific risks and evidence from large controlled trials remains insufficient.

### Is BioBran the same as AHCC or other mushroom immune supplements?

No — BioBran is arabinoxylan derived from rice bran hydrolyzed by Lentinula edodes (Shiitake) enzymes, whereas AHCC is a proprietary alpha-glucan-rich extract derived from cultured Shiitake mycelia. Both modulate NK cell function but through structurally distinct polysaccharide compounds, different receptor interactions, and separate bodies of clinical research.

### Does BioBran have any effect on viral infections like the flu or COVID-19?

BioBran's upregulation of NK cell activity and IFN-γ production provides a theoretical basis for antiviral immune support, and some in vitro and small human studies suggest improved immune surveillance against viral pathogens. However, no large-scale randomized controlled trials have specifically tested BioBran against influenza or SARS-CoV-2, so clinical claims in this area remain speculative and are not FDA-approved.

### What is the difference between BioBran and other arabinoxylan supplements?

BioBran is a proprietary extract of arabinoxylan from rice bran that has been extensively studied in clinical trials, particularly for its effects on NK cell activity. Unlike generic arabinoxylan supplements, BioBran's specific formulation and processing method have been validated in peer-reviewed research with documented immunological markers such as CD107a expression and interferon-gamma production. The branded ingredient ensures consistent potency and bioavailability compared to unbranded arabinoxylan sources.

### Is BioBran safe for children or immunocompromised individuals?

While BioBran enhances NK cell function, there is limited clinical safety data specifically in children and immunocompromised populations. Individuals with autoimmune conditions or those taking immunosuppressive medications should consult a healthcare provider before use, as enhanced immune cell activity could potentially interfere with their treatment. More targeted research is needed to establish safe dosing guidelines for these vulnerable populations.

### How strong is the clinical evidence supporting BioBran's immune benefits?

BioBran has moderate-level clinical evidence demonstrating increased NK cell activity, elevated immune cell populations, and enhanced cytotoxic potential (measured by CD107a expression) in human trials, including a 22-person study. However, most studies are relatively small in participant size, and larger, long-term randomized controlled trials are needed to establish definitive clinical efficacy for specific health outcomes. The mechanistic evidence is robust, but translational evidence linking these immune markers to disease prevention or treatment outcomes requires further investigation.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*